Xenon Pharmaceuticals Inc.
XENE
$58.81
-$0.74-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 12.11% | 0.92% | |||
| Gross Profit | -12.11% | -0.92% | |||
| SG&A Expenses | 0.47% | 7.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.64% | 2.33% | |||
| Operating Income | -9.64% | -2.33% | |||
| Income Before Tax | -6.15% | -0.14% | |||
| Income Tax Expenses | 77.25% | -577.88% | |||
| Earnings from Continuing Operations | -8.24% | 2.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.24% | 2.81% | |||
| EBIT | -9.64% | -2.33% | |||
| EBITDA | -9.72% | -2.37% | |||
| EPS Basic | 5.08% | 10.85% | |||
| Normalized Basic EPS | 6.92% | 8.14% | |||
| EPS Diluted | 5.08% | 10.85% | |||
| Normalized Diluted EPS | 6.92% | 8.14% | |||
| Average Basic Shares Outstanding | 14.04% | 9.01% | |||
| Average Diluted Shares Outstanding | 14.04% | 9.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||